Cargando…
Drug resistance in cancer
Cancer Research UK has recently sponsored a meeting, organized by the UK Medical Research Council, on cancer drug resistance. Several of the molecular mechanisms responsible for this clinical outcome, such as DNA interstrand crosslink repair, apoptosis evasion, cytochrome P450 and P-glycoprotein, we...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361669/ https://www.ncbi.nlm.nih.gov/pubmed/16234820 http://dx.doi.org/10.1038/sj.bjc.6602821 |
_version_ | 1782153270244933632 |
---|---|
author | Yagüe, E Raguz, S |
author_facet | Yagüe, E Raguz, S |
author_sort | Yagüe, E |
collection | PubMed |
description | Cancer Research UK has recently sponsored a meeting, organized by the UK Medical Research Council, on cancer drug resistance. Several of the molecular mechanisms responsible for this clinical outcome, such as DNA interstrand crosslink repair, apoptosis evasion, cytochrome P450 and P-glycoprotein, were discussed. There was a special focus on leukaemia, breast and ovarian cancer, and the potential use of positron-emission tomography to study anticancer-drug resistance. The progress made in translating these findings to the clinic, like Gefitinib, P-glycoprotein phenotyping, or genome-wide analysis technology, was also discussed. |
format | Text |
id | pubmed-2361669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23616692009-09-10 Drug resistance in cancer Yagüe, E Raguz, S Br J Cancer Meeting/Conference Report Cancer Research UK has recently sponsored a meeting, organized by the UK Medical Research Council, on cancer drug resistance. Several of the molecular mechanisms responsible for this clinical outcome, such as DNA interstrand crosslink repair, apoptosis evasion, cytochrome P450 and P-glycoprotein, were discussed. There was a special focus on leukaemia, breast and ovarian cancer, and the potential use of positron-emission tomography to study anticancer-drug resistance. The progress made in translating these findings to the clinic, like Gefitinib, P-glycoprotein phenotyping, or genome-wide analysis technology, was also discussed. Nature Publishing Group 2005-10-31 2005-10-18 /pmc/articles/PMC2361669/ /pubmed/16234820 http://dx.doi.org/10.1038/sj.bjc.6602821 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Meeting/Conference Report Yagüe, E Raguz, S Drug resistance in cancer |
title | Drug resistance in cancer |
title_full | Drug resistance in cancer |
title_fullStr | Drug resistance in cancer |
title_full_unstemmed | Drug resistance in cancer |
title_short | Drug resistance in cancer |
title_sort | drug resistance in cancer |
topic | Meeting/Conference Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361669/ https://www.ncbi.nlm.nih.gov/pubmed/16234820 http://dx.doi.org/10.1038/sj.bjc.6602821 |
work_keys_str_mv | AT yaguee drugresistanceincancer AT raguzs drugresistanceincancer |